20 Sep, 2021
Genor Announces Clinical Data on Geptanolimab at ESMO 2021

September 202021SHANGHAIChina - Genor Biopharma (Stock code: 6998.HK) today presented the latest clinical data on Geptanolimab (GB226) at ESMO (European Society for Medical Oncology) Congress 2021.


The European Society of Medical Oncology (ESMO) Congress 2021 was held virtually from 16 to 21 September 2021. Dr. SHI Yuankai, M.D. Professor of Medical Oncology Department of Medical Oncology Deputy Director of National Cancer Center, Vice President of Cancer Hospital Chinese Academy of Medical Sciences & Peking Union Medical College, orally presented the clinical data on September 19 (CEST). The clinical trial was designed to evaluate the efficacy and safety of Geptanolimab monotherapy in relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL).


The European Society of Internal Oncology (ESMO), founded in 1975, is the world's leading professional organization in oncology. The ESMO Congress is the most influential oncology platform designed in Europe for clinicians, researchers and healthcare industry representatives from all over the world to present the very latest advances in the treatment of cancer and offer an excellent educational program, with opportunities for an exchange of ideas among delegates from all around the world.


About GB226-003

Geptanolimab(GB226) in Chinese patients with relapsed or refractory primary mediastinal large B-cell lymphoma: Results from a multicenter, open-label, single-arm phase II trial. A team led by Dr. SHI Yuankai, M.D. evaluated the efficacy and safety of Geptanolimab (GB226) in the treatment of r/r PMBCL.


From October 22nd, 2018 to October 27th, 2020, 34 patients were screened and 25 eligible patients were enrolled among 19 centers in mainland China. The clinical results show that Geptanolimab (GB226) has demonstrated encouraging anti-tumor activity in r/r PMBCL patients with a manageable safety profile. Geptanolimab elicited a 64% ORRper Lugano 2014, and meaningful and sustained long term survival benefits to PMBCL patients, and provided a new treatment option for r/r PMBCL patients.